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Mechanisms to alter the expression of these enzymes in OA are potential therapeutic targets in what is currently a disease only treatable by joint replacement surgery.
Cellular proteins exist in a dynamic state with multiple pathways leading to their degradation, the best characterised being the ubiquitin-proteasome system (UPS). The UPS plays a pivotal role in the degradation of proteins important in numerous cellular processes including signal transduction pathways, a notable example being that of the NF-κB pathway via the regulation of IκB degradation. IκBs normally bind and sequester NF-κB dimers in the cytoplasm, but following their degradation the NF-κB complex translocates to the nucleus and regulates inflammatory signalling. Like most proteins destined for degradation via the UPS, IκB is covalently modified by the attachment of the small polypeptide ubiquitin (Ub).
Subsequently, additional Ub polypeptides can be covalently attached to the first Ub to create a poly-Ub chain that eventually directs the client protein for proteasomal degradation. [5, 6] Ub itself is a highly-conserved 76 amino acid polypeptide expressed by all eukaryotes. The covalent attachment of Ub to cellular proteins, ubiquitination, occurs at lysine (K) residues.
Ub itself contains seven K residues which allows for different poly-Ub chains to be generated including K48 chains which target proteins to the proteasome. K63 and linear Ub chains have emerged as having important roles in signal transduction pathways, the most studied again being the NF-κB pathway. [6] The aim of this study was to investigate the role of Ub and the UPS in the induction of OA in a murine model and to identify novel targets of Ub, all of which may have potential therapeutic relevance. 
METHODS

Cells, samples and treatments
This study was performed with Ethical Committee approval from the Newcastle and North
Tyneside Health Authority, UK. Human articular chondrocytes (HACs) were from consenting patients undergoing knee joint replacement surgery and were isolated and cultured as described. [7] Human chondrosarcoma cells (SW1353) were cultured as described. [8] Cells were seeded one day before treatment and cultured in serum-free medium overnight prior to stimulation. Cells were stimulated with human recombinant IL-1α (0.5 ng/ml) or 0.5 µg/ml poly(I-C) (Invivogen, Source BioScience LifeSciences, Nottingham, UK). Where indicated, cells were treated 1 h before and during stimulation with MG132 (5 µg/ml) (Tocris biosciences, R&D Europe Ltd. Abingdon, UK or Sigma-Aldrich Ltd. Poole, UK).
Gene depletion/RNA intereference (RNAi)
Cells were transfected with siRNA (50 nM) for 48 h using Dharmafect 1 (Dharmacon, Thermo
Fisher Scientific, Epsom, UK) according to the manufacturer's protocol and as described previously. [7, 8] The following siRNAs were used: siGENOME SMARTpool: siGenome TRAFD1
siRNA (M-004097-01-0005) and siGenome Non-targeting siRNA pool #2 (D-001206-14-
20)(siCon)(Dharmacon).
Immunoblotting
Whole cell lysates were prepared as described but supplemented with 20 mM Nethylmaleimide, to block deubiquitination. [7] Protein extracts were separated by SDS-PAGE, transferred to PVDF or nitrocellulose membranes and probed with the following antibodies:
anti-IκBα; anti-phospho-NF-κB p65; anti-FLAG (Cell Signaling, New England Biolabs (UK) Ltd, Hitchin, UK); anti-GAPDH (Chemicon, Millipore (U.K.) Ltd., Watford, UK); anti-TRAFD1 (Santa Cruz Biotechnology (SCBT), Inc., Insight Biotechnology Ltd., Wembley, UK), and antiUbiquitin (Dako UK Ltd, Ely, UK). 
Enrichment of proteins with Tandem Ubiquitin Binding Entities (TUBES)
SW1353
Mass spectrometric analysis and data analysis
MS was performed by Dundee Cell Products Ltd. (Dundee, UK) on an UltiMate™ 3000 nLC (Thermo scientific) coupled to a LTQ Orbitrap XL (Thermo Scientific). RAW data files were extracted with Raw2MSM and searched using Mascot Search Engine. A maximum of 2 missing tryptic cleavages and the following modifications were selected for database search criteria: fixed modifications: Carbamidomethyl (C); variable modifications: Acetyl (N-term), Dioxidation (M), Gln->pyro-Glu (N-term Q), Oxidation (M), with/without GlyGly (K). The relative quantification of proteins (spectral count) was performed using an exponentially modified abundance index (emPAI) as described.
[10]
TRAFD1 cloning and immunoprecipitation
A human TRAFD1 ORF clone, IRQMp5018H057D (Source Bioscience), was PCR amplified using primers 5'-CAGTGTGGTGGAATTTCGTCCCTGGAAGAGCTAAA-3' and 5'-GATATCTGCAGAATTCTCCTCCTCTTCCTCTTCTGC -3' and subcloned into a modified pcDNA4
(Life Technologies, Paisley, UK) vector using In-Fusion (Takara Bio Europe/Clontech, SaintGermain-en-Laye, France) to create a C-terminal FLAG-tag fusion protein. Bound proteins were washed once with lysis buffer and twice with TBS-T and   eluted with 50 µl 2 x Laemmli sample buffer prior to SDS-PAGE and immunoblotting with the anti-FLAG or anti-Ub (after autoclaving of membranes) antibodies.
Real-time reverse transcription-PCR
Total RNA from cells was extracted using Cells-to-cDNA II kit, RNAse-free DNAse (Life Technologies) treated, and cDNA synthesised as described.
[11] Primers and probes were as published [7] or designed by the Universal Probe Library (Roche Applied Science, Burgess
Hill, UK) and were: TRAFD1 F 5'-CAGCCTCAAGAGACCTCACC-3' and R 5'-TCCAGGTAACCAGAAGACAGGT-3' with probe#44; IL6 5'-GATGAGTACAAAAGTCCTGATCCA-3'
and R 5'-CTGCAGCCACTGGTTCTGT-3' with probe#40. Real-time RT-PCR performed and analysed as described.
[12]
In vitro cartilage degradation assay
Cultured bovine cartilage discs were incubated with serum-free DMEM containing IL-1 (1 ng/ml) and Oncostatin M (OSM) (10 ng/ml) ± DMSO/or MG132 (5 µg/ml) and refreshed on day 7. Residual cartilage explants were papain digested overnight at 65 o C. Hydroxyproline (OHPro) and glycosaminoglycan (GAG) release were assayed as described. [13] Conditioned media was assessed at day 7 and 14 (presented) for damaged cells using the ToxiLight™ BioAssay Kit (Lonza, Slough, UK). Day 0 cartilage was freeze-thawed thrice as a positive control of cell damage. 
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RESULTS
Inhibition of the proteasome reduces cartilage destruction and MMP13 expression
MG132 reduces the degradation of ubiquitin-conjugated proteins by the 26S proteasome complex and because this diverts ubiquitin pools into futile conjugates it has the effect of disrupting Ub homeostasis. Since poly-ubiquitination is strongly associated with NF-κB signal transduction, [20] we evaluated the effect of MG132 on cytokine-induced cartilage destruction using an established bovine cartilage model. [13] MG132 completely ameliorated the cartilage damage, as measured using glycosaminoglycan (GAG) and hydroxyproline (OHPro) release as surrogates for aggrecan and collagen destruction, mediated by the IL-1+OSM combination ( Fig. 1A and B) . Potential cytotoxicity of the MG132 treatment was assessed at day 7 and 14 (presented Fig. 1C ) and showed low toxicity compared to freeze-thawed cartilage or the IL-1+OSM cytokine combination.
Cartilage-collagen turnover is mediated by MMPs, with MMP13 the accepted collagenase in OA. In both HAC and SW1353 cells, MG132 completely abolished the IL-1 or poly(I-C) (pIC)
induced MMP13 expression, the latter stimulus being a double-stranded RNA mimic which is a potent inducer of MMP13 in HAC (Fig 1D) . [7] Since IL-1 and poly(I-C) activate the NF-κB signalling pathway, we examined the effect of MG132 on the activation of this pathway by assessing the phosphorylation status of the NF-κB component p65 and the degradation of IκBα, which is a consequence of K48 poly-ubiquitination. Interestingly, MG132 caused an increase in P-p65 even under basal conditions, as has previously been reported.
[21] Using an early time-point of stimulation (15 min), at which IκBα degradation is initiating, [7, 8] we observed MG132 caused an increase in higher molecular weight IκBα immune-reactive products which we ascribed to be K48 poly-ubquitinated forms (Fig 1E) .
Inhibition of the proteasome reduces induced-OA in mice
Given the ability of MG132 to protect against cytokine-induced cartilage destruction, we tested the efficacy of the compound in the murine DMM model of post-traumatic OA.
MG132 was delivered systemically post-surgery for the eight week duration of the experiment at which point OA was assessed by histological scoring. [16] significantly reduced cartilage damage in the most affected medial-tibial plateau but showed little evidence of efficacy for the less damaged femoral condyle ( Fig. 2A and B) .
Summation of the medial-femoral and tibial histological scores demonstrated an overall protection of cartilage loss in MG132 administered animals (Fig. 2B) . Similarly to other studies (e.g. [22] ), the administration of MG132 at this dose and for this length of time had no effect on the activity/wellbeing of the mice and had no impact on the weight of the animals.
K48 poly-ubiquitination plays a role in DMM-induced OA
To determine the mechanism by which MG132 protected the mice from induced-OA, we performed DMM surgery on transgenic mice expressing one of three mutated forms of Ub, unable to form specific poly-Ub chains, in addition to their endogenous Ub genes.
[18] When examining the medial tibial plateau none of the mutant-Ub mice were protected from OA with in fact a significant enhancement of the OA score of the K63R mice ( Fig. 3A and B ).
However, the medial femoral condyles of the K48R mice showed a significant reduction in the OA score compared to either 'wild-type' animals or 'wild-type' Ub transgenic animals ( Fig. 3A and B) . Overall summation of the histological scores from both medial plateaus revealed no significant differences between transgenic and 'wild-type' animals ( Fig. 3B ).
TRAFD1 positively regulates induced MMP13 expression
Many components of signalling pathways are known to be modulated by Ub conjugation.
Therefore we attempted to identify novel proteins ubiquitinated under either basal or stimulated conditions which may be important OA given our mouse-model findings, using chondrosarcoma SW1353 cell extracts. Ubiquitinated proteins were first enriched using TUBEs which have a nanomolar binding affinity for poly-ubiquitinated proteins. [9] After confirmation of the enrichment of Ub conjugated proteins (Fig. 4A , mid-panel), proteins were identified by MS using spectral counts to quantify relative abundance. We identified 176 proteins in total and the protein with the highest emPAI (exponentially modified protein abundance index) was ubiquitin in all samples (Supplementary table) . Identified proteins with a reported role in NF-κB signalling are listed (Table 1) . Of these, TRAFD1 was identified only under basal conditions and has been identified as a negative regulator of cytokine 4C ) and measured IL-1-or poly(I-C)-induced gene expression. Depletion of TRAFD1 reduced both basal and induced expression of MMP13 (Fig. 4D ). Previous work with TRAFD1 had focussed on IL6 regulation, again similar to our findings with MMP13, we observed a reduction in induced IL6 expression following TRAFD1 depletion (Fig. 4E ). pheno-copying the MG132 data, K48R transgenic animals showed significant protection from DMM-OA, but only on the less affected medial-femoral condyle, suggestive of a delay in OA-onset. These data warrant further investigation into the role of K48 polyubiquitination at earlier time points during DMM where lesions on the tibial plateau are initiating. A limitation of these studies is that all the transgenic mice are still able to make all poly-Ub conjugates because they still express the four copies of the endogenous Ub genes, UBA52, RPS27A, UBB and UBC, [30] although data suggest the transgenic mutant Ub acts as a dominant negative form.
[18] A further limitation is that the transgenic animals were maintained on FVB/N genetic background, rather than C57Bl/6, although we still observed reduced OA in K48R mice compared to the WT-Ub transgenics or 'WT' C57Bl/6 mice, which themselves developed OA indistinguishable from each other (Fig 3) . 0.05 
magnification). (B). Approximately fourteen sections
from each mouse were graded by two blinded scorers using a validated scoring system. [16] The means of the highest score for each animal are plotted (n=8 per group) for the medial 
UPS inhibition prevents cartilage destruction via blockade of NF-κB signaling to MMP13. (A) and (B)
. Bovine nasal cartilage was cultured in serum-free medium in the presence of either medium, or medium plus IL-1 and OSM both ± MG132 or DMSO vehicle as described for 14 days. (A) Glycosaminoglycan (GAG) release into the medium was assayed using the dimethylmethylene blue assay [13] and is shown for day 7.
(B). The levels of collagen fragments released into the medium were determined by measurement of hydroxyproline (OHPro). [13] Results shown are for the cumulative collagen release at day 14 of culture and expressed as a percentage of the total (mean ± SD). Experiments were performed with three bovine noses with each experiment performed in quadruplicate. (C). Treatment toxicity was measured in condition medium (day 7 and 14 -presented) using the ToxiLight™ BioAssay Kit. Data is average (n=4) emitted light from a single bovine cartilage experiment with freeze-thawed cartilage used as a positive control and set to 100% toxicity. (D). SW1353 cells or HAC were stimulated with ligands (pIC = poly(I-C)) ± MG132 or DMSO vehicle, as described and labelled, for 6 h or 24 h respectively. MMP13 and 18S expression were measured using real-time RT-PCR. (E). SW1353 cell were stimulated as described for 15 min and isolated protein subjected to immunoblotting with the indicated antibodies. GAPDH was used as a loading control. Real-time PCR results are combined data from 3 separate experiments (n=4/experiment) or representative of two patient HAC. Immunoblotting is representative of two experiments. 186x192mm (300 x 300 DPI) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 
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